Lurasidone 40 mg Improved Five PANSS Symptom Domains in Acute Schizophrenia

Lurasidone 40 mg Improved Five PANSS Symptom Domains in Acute Schizophrenia

TL;DR: A 2026 post-hoc analysis in International Clinical Psychopharmacology found that lurasidone 40 mg/day improved all 5 Positive and Negative Syndrome Scale (PANSS) symptom domains in acute schizophrenia over 6 weeks, with the largest effect on positive symptoms and later improvement in negative symptoms. Key Findings 483 randomized patients: The JEWEL phase 3 trial assigned …

Read more

TACS for Schizophrenia: Early Promise of Transcranial Alternating Current Stimulation

Schizophrenia is a severe mental disorder affecting about 1% of the population worldwide. It is characterized by hallucinations, delusions, disorganized thinking and behavior, and impaired cognitive functioning. Current treatments with antipsychotic medications are helpful but have significant limitations, especially for cognitive deficits and negative symptoms like social withdrawal and lack of motivation. This has driven …

Read more